This site is intended for healthcare professionals
CDK4/6 inhibitors in breast cancer

Congress highlights

Read time: 15 mins
Last updated:20th Jan 2021
Published:20th Jan 2021
San Antonio Breast Cancer Symposium (SABCS) 2020

Nadia Harbeck.jpgProfessor Nadia Harbeck, the Scientific Director of the WSG and Head of the Breast Centre at LMU Klinikum Munich in Germany, shares her views on the most exciting topics presented at SABCS 2020. In 2020, SABCS comprised of a five–day virtual program attended by a broad and international audience, with new data and updates from the monarchE, PENELOPE-B and MONALEESA studies amongst other topics.

The annual San Antonio Breast Cancer Symposium (SABCS) was held virtually for the very first time in December 2020 and presented the latest state-of-the-art information on breast cancer. 

This year, SABCS 2020 comprised of a five–day program attended by a broad international audience and included the first results from the PENELOPE-B trial and the final invasive disease-free survival (IDFS) analysis of monarchE.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Amongst the most important data that emerged from SABCS 2020 were from Dr Nadia Harbeck who presented data from the ADAPT trial (NCT01779206)1 

and showed that certain patients with luminal EBC and up to 3 involved lymph nodes can be treated with adjuvant endocrine therapy (ET) according to the primary outcome analysis.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Professor Harbeck provides an expert opinion on the most exciting discussion points at SABCS 2020 related to CDK4/6 inhibition in breast cancer.

Updates from the monarchE trial (NCT03155997)1 were key at SABCS 2020.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Professor Harbeck from the Breast Centre at LMU in Munich, Germany gives an overview of the impact of the findings on treating early breast cancer patients.

Besides the results from the monarchE trial and their impact discussed above, the data from the ADAPT study highlight the role of Oncotype DX Breast Recurrence Score test in shaping clinical practice.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: